|
A new study has raised questions among researchers regarding a
theory that has entered the common wisdom – that “good cholesterol”
reduces the risk of heart attacks. Pharmaceutical companies have
spent more than a billion dollars pursuing this theory, to limited
results.
The study found that among people with a genetic condition that
severely limits their levels of HDL (or “good”) cholesterol were
no more likely to suffer from a heart attack than those with normal
amounts of the HDL cholesterol.
The study was published in the Journal of the American Medical
Association. Prior studies found that HDL cholesterol ferried
dangerous plaque out of the body, which lead many to believe that
patients with low HDL cholesterol levels would have a much higher
risk of heart attack.
The major pharmaceutical companies have sent years of time and
hundreds of millions of dollars after drugs that increase HDL
cholesterol production. This new study may show that all their
efforts were wasted. Anne Tybjaerg-Hansen, one of the authors
of the study and a clinical biochemistry researcher at Copenhagen
University Hospital, told Bloomberg, “There is really no evidence
that this method is going to work. `This theory has been around
for a long time, but this study just doesn't support it.''
The misconception may have originated when researchers chose their
subjects for HDL cholesterol studies. Most of the patients had
high levels of triglycerides. The high levels of triglycerides
may have caused the increased risk of heart attack, not their
low HDL cholesterol levels.
Even so, Yale Mitchel, vice president of cardiovascular disease
research for Merck, says the study won’t stop his work in HDL-raising
drugs.
"The hypothesis on whether CETP inhibition is a benefit
or not hasn't been tested and it is too attractive a mechanism
to disregard right now," said Mitchel. "We have to be
careful about not over interpreting it at this point. There is
a large contextual database that suggests low HDL levels are associated
with an increased risk.''
|